Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib

Understanding the genetic mechanisms of sensitivity to targeted anticancer therapies may improve patient selection, response to therapy, and rational treatment designs. One approach to increase this understanding involves detailed studies of exceptional responders: rare patients with unexpected exqu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wagle, Nikhil, Grabiner, Brian C., Van Allen, Eliezer M., Hodis, Eran, Jacobus, Susanna, Supko, Jeffrey G., Stewart, Michelle, Choueiri, Toni K., Gandhi, Leena, Cleary, James M., Elfiky, Aymen A., Taplin, Mary Ellen, Stack, Edward C., Signoretti, Sabina, Loda, Massimo, Shapiro, Geoffrey I., Sabatini, David, Lander, Eric S., Gabriel, Stacey B., Kantoff, Philip W., Garraway, Levi A., Rosenberg, Jonathan E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4122326/
https://ncbi.nlm.nih.gov/pubmed/24625776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0353
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados